Ratings SomnoMed Limited

Equities

SOM

AU000000SOM1

Market Closed - Australian S.E. Other stock markets 10:41:24 2024-06-02 pm EDT			5-day change	1st Jan Change
0.27 ^AUD	-3.57%		+3.85%	-46.00%

May. 13	SomnoMed Pays Loan from Epsilon Direct Lending; Shares Rise 5%	MT
May. 05	SomnoMed Completes AU$16.8 Million Retail Entitlement Offer	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.53 for the 2024 fiscal year.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
SOMNOMED LIMITED	-46.00%	40.18M	-
ABBOTT LABORATORIES	-7.16%	178B	C+
MEDTRONIC PLC	-1.23%	107B	C
BECTON, DICKINSON AND COMPANY	-4.86%	67.04B	A
DEXCOM, INC.	-4.28%	47.23B	B-
CENCORA, INC.	+10.32%	44.62B	B-
HOYA CORPORATION	+9.25%	42.5B	B+
TERUMO CORPORATION	+15.97%	25.22B	A-
WEST PHARMACEUTICAL SERVICES, INC.	-5.88%	24.14B	A-
ZIMMER BIOMET HOLDINGS, INC.	-5.38%	23.69B	B

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes